Menu Close Menu

Fewer cancers.
Better survival.
Equity for all.

Systemic Anti-Cancer Therapy Regimen Library

SKIN Melanoma NON-Metastatic - nivolumab Q4W [flat dosing]

Treatment Overview

Cycles 1 to 13 - 28 days

Cycle length:
28

Cycle details

Cycles 1 to 13 - 28 days

Medication Dose Route Days Max Duration
nivolumab 480 mg flat dosing intravenous 1 30 minutes

Full details

Cycles 1 to 13 - 28 days

Day: 1

Medication Dose Route Max duration Details
nivolumab 480 mg flat dosing intravenous 30 minutes
Instructions:
Administer via a sterile, non-pyrogenic, low protein binding 0.2 to 1.2 micron in-line filter.

Supportive Care Factors

Factor Value
Emetogenicity: Minimal
Hypersensitivity / Infusion related reaction risk: Low - routine premedication not recommended

* The medicines, doses, combinations, and schedule in this treatment regimen have been carefully reviewed against international best practice guidelines by specialists in medical oncology around New Zealand and this advice has been accepted for publication by Te Aho o Te Kahu (the Cancer Control Agency). Sometimes medicines that are used in routine clinical practice have not been through a formal review process by the NZ Medicines Regulator Medsafe and are therefore considered unapproved or off-label. These medicines are legally able to be prescribed through sections 25 and 29 of the Medicines Act and by obtaining informed consent from patients. All treatment regimens listed on this website have been through robust peer review and are considered an accepted standard of care, whether prescribed through sections 25 or 29 or carrying formal Medsafe Approval.

s29: This symbol indicates that some formulations of the associated medicine are legally only able to be prescribed under section 29 of the Medicines Act. You can see which formulations are section 29 by hovering over the s29 symbol. You can access full medication details from the New Zealand Formulary by clicking on the medication name. Each clinician retains full responsibility for ensuring they have complied with all relevant obligations and requirements of section 29 including obtaining informed patient consent prior to prescribing the applicable medicine.